Article
Roche's MS blockbuster Ocrevus, facing new Novartis competition, scores FDA nod for more-convenient
Rating:
0.0
Views:
138
Likes:
1
Library:
1
As Novartis launches its self-administered multiple sclerosis drug Kesimpta, rival Roche has been looking for a convenience boost with its earlier-to-market blockbuster Ocrevus—and it just snagged an FDA go-ahead toward that goal.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value